Subscribe to Bioshares \$500/ 48 issues

More details can be found on the back page

Companies covered: AVR, CUV, MX1, NSB, PAB, tafenoquine

-	
	Bioshares Portfolio
Year 1 (May '01 - May '02)	21.2%
Year 2 (May '02 - May '03)	-9.4%
Year 3 (May '03 - May '04)	70.6%
Year 4 (May '04 - May '05)	-16.3%
Year 5 (May '05 - May '06)	77.8%
Year 6 (May '06 - May '07)	17.4%
Year 7 (May '07 - May '08)	-35.8%
Year 8 (May '08 - May '09)	-7.4%
Year 9 (May '09 - May '10)	50.2%
Year 10 (May '10 - May'11)	45.4%
Year 11 (May '11 - May '12)	-18.0%
Year 12 (May '12 - May '13)	3.1%
Year 13 (May '13 - May '14)	26.6%
Year 14 (May '14 - May '15)	23.0%
Year 15 (May '15 - May '16)	33.0%
Year 16 (May '16 - May '17)	16.8%
Year 17 (May '17 - May '18)	-7.1%
Year 18 (May '18 - May '19)	-2.3%
Year 19 (May '19 - May '20)	39.5%
Year 20 (May '20 - Current)	12.4%
Cumulative Gain	1124%
Av. Annual gain (19 yrs)	17.3%

Bioshares is published by Blake Industry & Market Analysis Pty Ltd.

Blake Industry & Market Analysis Pty Ltd ACN 085 334 292 PO Box 193 Richmond Vic 3121 AFS Licence No. 258032 Enquiries for *Bioshares* Ph: (03) 9326 5382 Fax: (03) 9329 3350 Email: info[at]bioshares.com.au

David Blake - Editor/Analyst Ph: (03) 9326 5382 Email: david[at]bioshares.com.au

Mark Pachacz - Editor/Analyst Ph: 0403 850 425 Email: mark[at]bioshares.com.au

Individual Subscriptions (48 issues/year) \$500 (Inc.GST) Edition Number 852 (20 July 2020)

Copyright 2020 Blake Industry and Market Analysis Pty Ltd. ALL RIGHTS RESERVED. Secondary electronic transmission, photocopying, reproduction or quotation is strictly prohibited without written consent of the publisher.

Bioshares

20 July 2020 Edition 852

Delivering independent investment research to investors on Australian biotech, pharma and healthcare companies

Patrys – Synthetic Lethality to Kill Cancer Cells

Patrys (PAB: \$0.13) is operating in a promising area of oncology, termed 'Synthetic Lethality'. It is one of four approaches to treating cancer that both GlaxoSmithKline and AstraZeneca have committed to, with recent major deals in the area by GSK and Bristol-Myers Squibb (BMS).

Patrys is a stock that is flying under the radar, quietly arranging the manufacture of its lead antibody drug candidate, PAT-DX1, ahead of preclinical toxicology and then the first clinical trial around the end of 2021. However, given the nature of recent deals, a licensing deal may be on the cards before its compound even enters the clinic.

The technology Patrys is commercialising stems from research conducted, and which continues, at Yale University. Researchers identified circulating autoantibodies from patients which lupus, which passed the cell membrane and entered the cell nucleus, with this aberrant function responsible for the manifestation of the disease.

A non-harmful antibody, Deoxymab 3E10 was isolated, with an improved humanised antibody fragment developed, PAT-DX1, which has become the company's lead drug candidate.

The features of this antibody platform are that the antibodies can penetrate the bloodbrain-barrier (with glioblastoma the first likely indication), are attracted to the cancer cells due to the DNA discharge from cancer cells, have the ability to enter the cell nucleus, and are relatively harmless to normal cells, but promote cancer cell death by disrupting DNA repair in cells that already have a compromised DNA repair process (which is the nature of cancer cells).

DNA Damage Response (DDR) Pathways

Patrys CEO James Campbell said that there are five major DNA Damage Response (DDR) pathways. As cancer cells develop causing abnormal cell growth, they lose some of their DNA repair machinery in at least one of those five pathways according to Campbell.

However, "blocking an additional pathway by therapeutic means should deactivate the whole DDR system in cancer cells and lead to cancer cell death" is a process that is now referred to as 'synthetic lethality'.

The approach is not hypothetical research fancy, with PARP inhibitors, which interrupt DNA damage repair, already on the market and generating billions of dollars in sales.

Success of PARP (DDR) inhibitors

In 2019, GlaxoSmithKline acquired oncology company Tesaro for US\$5.1 billion, largely for its PARP inhibitor Zejula, which was first approved by the FDA in 2017 for the treatment of ovarian cancer in patients with the BRCA mutation. In April this year, that indication was broadened to all ovarian cancers (in patients who have had a full or partial response to chemotherapy). Zejula sales last year were US\$295 million.

Bioshares

– Patrys cont'd

AstraZeneca sees the DDR therapy field as "an exciting area of science". Its PARP inhibitor, Lynparza (which is shared with Merck) generated sales of US\$1.2 billion last year. The drug was first approved in 2014 for the treatment of ovarian cancer (in patients with the BRCA mutation). It has since gained approval for the treatment of breast, pancreatic and prostate cancers.

There is strong interest in DDR therapies, including novel DDR treatment pathways, with combinations of multiple DDR therapies an obvious pursuit. This places Patrys with PAT-DX1 in a very good position if it can complete its cell line development for manufacture and clear the preclinical toxicology program.

Recent Deals for DDR Programs

Of interest to Patrys are the early stage deals that have occurred this year in the DDR therapy space.

In June this year, GSK partnered with US biotech Ideaya paying US\$100 million upfront and also invested US\$20 million to access three preclinical programs from Ideaya that are using the 'synthetic lethality' approach to treating cancer (using gene-editing to fine pairs of mutations to target). The programs are three years away from clinical trials.

In May this year BMS signed a discovery deal with Repare Therapeutics from Canada which included US\$65 million in upfront and equity investment and up to US\$3 billion in future milestone payments and fees. Rapare Therapeutics uses a gene-based screening approach to identify synthetic lethal gene pairs in patients to achieve cancer cell destruction.

Timeline

Patrys expects cell line development to be completed by the end of this year which will allow it to then produce commercial quantities of PAT-DX1. Formal toxicology studies are expected to start in the first half of next year, ahead of clinical studies around the end of 2021.

Funding

At the end of March, Patrys had \$4.7 million in cash. It is currently conducting a fully underwritten rights issue to raise an additional \$4.3 million at \$0.012 a share.

Pre-clinical Results with PAT-DX1

In mouse studies (conducted at the Yale School of Medicine), the company showed that breast cancer metastases could be reduced by 93% with PAT-DX1 over the control.

In a mouse glioblastoma study (also conducted at the Yale School of Medicine) it was shown that PAT-DX1 reduced tumour growth by 83% using highly aggressive human glioblastoma tumours.

The Patrys Board

The board of Patrys includes several highly experienced directors. Dr Pamela Klein was formerly VP of Development at Genentech and Suzy Jones spent 20 years at Genentech in business and product development.

Summary

Patrys is capitalised at \$18 million (following the rights issue). The company will be funded to complete its preclinical development of PAT-DX1, at which point, an attractive licensing transaction is a possibility for this unique approach of synthetic lethality to destroy cancer cells.

Bioshares recommendation: Speculative Buy Class B

(Patrys has been added to the Bioshares Model Portfolio)

Anteris Technologies (AVR: \$3.81) has assembled an experienced advisory board to support the company's development of its novel 3-D transcatheter aortic valve replacement (TAVR) device.

The company is currently undertaking a study in Belgium of ADAPT-treated leaflets in a valve repair trial, so far with very promising results. Anteris' tissue treatment technology addresses the calcification limitation that affects the valve leaflets made from bovine or porcine pericardium tissue. Calcification has limited the use of implantable valves in younger patients requiring heart valves, usually to address the problem of stenosis. In stenosis, valves which don't close properly cause regurgitation and degrade heart function.

The company's goal is to develop a single piece aortic valve that can be implanted using the transcatheter route, in contrast to the more invasive open surgery. The company has to date evaluated its TAVR approach in three pigs (porcine model) with data expected by year's end from a total of nine animals.

TAVR is becoming more accepted as an implantation method following the publication of several studies in recent years which have shown it to be non-inferior to surgery, and in one study (PARTNER 3) delivering lower rates of all-cause deaths, stroke, rehospitalisation and bleeding.

Medical Advisory Board

The value of medical or scientific advisory boards to small R&D companies can vary. Their value relates to not only credentials

and experience of their members but more importantly how they can shape and guide a company's clinical development and commercialisation plans. Clinically active advisors may also be key opinion leaders in their own right.

Membership may or may not be compensated. If compensation is not much more than a basic honorarium, then the presence of distinguished figures may indicate a company has attracted the interest of leading researchers or physicians with a keen and genuine interest in a potentially worthwhile technology.

Members of the Anteris Medical Advisory Board are listed in the table below. Leading members include: Dr Michael Reardon, from Houston Methodist, with 55 publications relating to randomised clinical trials to his credit; Dr Samir Kapadia from the Cleveland Clinic (57 publications); and Dr Susheel Kodali from Colombia University Medical Clinic (63 publications).

Most of these advisory board members have been involved in the clinical trials of TAVR devices.

It is rare for an ASX-listed medical device company to have assembled an advisory board with this depth of experience, and is an indicator of a high degree of clinical interest in Anteris' technology.

Several members of the Anteris advisory board have discussed Anteris' ADAPT technology at recent meetings.

Cont'd over

Anteris Advisory Board			Select Trials				
Clinician	Affiliation	Pubmed RCT Pubs	Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement	Transcatheter Aortic- Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patient	Transcatheter Aortic- Valve Replacement with a Self-Expanding Valve in Low-Risk Patients	Two-Year Outcomes After Transcatheter Aortic Valve Replacement With Mechanical vs Self- expanding Valves	
Trial Publication		•	PARTNER 2 NEJM (Feb 2020)	PARTNER 3 NEJM (May 2019)	ΝΕJΜ (Μaγ 2019)	REPRISE III JAMA (Feb 2019)	
Device, Manufacturer			NEJM (Feb 2020) SAPIEN XT, Edwards	IVEJIVI (MAY 2019)	Evolut, Medtronic	Lotus (Mechanical), Boston Scientific, CoreValve (Self- expanding (Medtronic)	
Dr Paul Sorajja	Abbott Northwestern Hospital, Minneapolis Heart Institute (Valve Science Centre)	7	Investigator		Author		
Dr Michael Reardon	Houston Methodist	55			Author	Author	
Dr Samir Kapadia	Cleveland Clinic	57	Author	Author			
Dr Jeffery Popma	Harvard Medical	6			Author		
Dr Gorav Ailwadi	University of Virginia Health System	1					
Dr Susheel Kodali	Colombia University Medical Center	63	Author	Author			
Dr Vinayak Bapat	New York Presbyterian/Colombia Medical	0					
Dr Alan Zajarias	Center for Advanced Medicine, Heart and Vascular, Washington University in St Louis	23	Author	Investigator			
Dr Christopher Meduri	Piedmont Heart Institute, Atlanta	5			Investigator	Author	

Company	Code	Price (current)	Price added to portfolio	Recommend- ation	Cap'n (\$M)	Date added	Portfolio Changes - 20 July, 2020
Opthea	OPT	\$2.320	\$0.160	Spec Buy A	\$624	November 2014	
Volpara Health Technologies	VHT	\$1.400	\$0.375	Spec Hold A	\$349	June 2017	IN:
Telix Pharmaceuticals	TLX	\$1.315	\$0.910	Spec Hold A	\$333	May 2019	Patrys has been added
Cyclopharm	CYC	\$1.500	\$1.35	Spec Buy A	\$117	September 2019	at \$0.013
Somnomed	SOM	\$1.360	\$0.94	Spec Hold B	\$113	January 2011	
Immutep	IMM	\$0.180	\$0.320	Spec Buy A	\$88	March 2019	OUT:
Cogstate	CGS	\$0.405	\$0.24	Spec Buy A	\$69	April 2019	No changes
Dimerix	DXB	\$0.340	\$0.09	Spec Buy A	\$67	December 2018	
Micro-X	MX1	\$0.165	\$0.38	Spec Buy A	\$59	May 2017	
Pharmaxis	PXS	\$0.090	\$0.260	Spec Buy B	\$36	December 2016	
Acrux	ACR	\$0.150	\$0.31	Spec Buy A	\$25	July 2017	
Rhinomed	RNO	\$0.082	\$0.24	Spec Hold B	\$21	Jun-19	
Patrys	PAB	\$0.013	\$0.01	Specu Buy B	\$19	July 2020	
Adalta	1AD	\$0.092	\$0.07	Spec Buy B	\$15	May 2020	
Stocks Removed from Bio	shares	Portfolio in	ттм			•	•
Date removed	Stock						
September 2019	1AD, ALC	C, BCT					

Anteris cont'd

At the 2019 Cardiovascular Innovations Foundation meeting, Anteris Advisory Board member Dr Alan Zajarias said that "the next big advancement where valve replacement will come from is not necessarily in modifying the frames but from modifying the leaflet tissue." He said there were two advances to note including Edwards Life Sciences' Resilia and (Anteris') ADAPT. "So with these advances hopefully we will get better, longer durable valves."

https://cvinnovations.org/2019-archive/ https://www.youtube.com/ watch?v=GK1GIviPCjY&feature=youtu.be

At the same meeting, a six minute presentation prepared by Dr Paul Sorajja, "Tissue Processing for Durability – A Novel TAVR", was presented by Dr Gilbert Tang in the first public presentation of the Anteris ADAPT technology used to make a single piece TAVR.

He discussed other rival alternatives in development which include Xeltis (a bio-resorbable polymer frame), Strait (a biopolymer) and the Inspirus TAVR which is made using Edwards Life Sciences' Resilia process.

Tang said that what the ADAPT processing achieved was to have residual DNA and no calcium binding sites, so preventing calcification. Other tissue methods cited which did lead to calcification included Xenosure, XenoLogiX, Photofix, Fresh BP and CoreMatrix.

He further discussed how an approach called Samurai tissue thinning could be used to thin pericardium and give the tissue a smooth, uniform thickness of 20 to 40 microns, allowing the tissue to be packed into small spaces. Samurai tissue thinning "increases pericardium yield – you don't need to buy as much pericardium – and it maintains its mechanical properties and enables 3-D molding." Tang also said that 15 stitches were needed to attach the valve compared to 150 stitches for a current TAVR valve. The valve could also be implanted in an inverted position on a frame, which means that a much smaller dimension catheter can be used.

https://www.youtube.com/watch?v=yqbQTf6PcE&feature=youtu.be

Summary

We have upgraded our recommendation for Anteris Technologies to Speculative Buy Class B in recognition of the interest the company has received and is likely to receive from interventional cardiologists, and also the prospects for commercial advances to take place in coming months.

Anteris Technologies is capitalised at \$23 million.

Bioshares recommendation: Speculative Buy Class B

Arakoda (tafenoquine) for SARS-CoV-2 and COVID-19 – A Potential Treatment in the Out-patient Setting and for Post-Exposure Prophylaxis

US specialty pharmaceutical company Sixty Degrees Pharma has released preclinical data which shows the effects of its aminoquinoline compound Arakoda (tafenoquine) against the coronavirus SARS-CoV-2.

Arakoda (tafenoquine) is an 8-aminoquinoline whereas Plaquenil (hydroxychloroquine) (HCQ) is a 4-aminoquinoline.

HCQ is being evaluated in 195 clinical studies, planned or underway for the treatment of SARS-CoV-2 infection. A feature of HCQ is that it is administered orally.

Tafenoquine was approved in the USA in 2018 as a prophylaxis for malaria. Its brand name in Australia is Kodatef.

Tafenoquine is formulated as a 100mg tablet. Prior to travel into areas in which malaria is common, a patient receives 200mg once daily for three days as a loading dose, followed by a 200mg weekly dose while in an area with malaria, and then a terminal dose of 200mg seven days after leaving the area.

The drug is contraindicated for patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and patients with psychotic disorders or symptoms.

It has also been established that tafenoquine has a low cardiotoxicity risk, which is an issue for HCQ.

Results from Evaluations

Sixty Degrees began its testing in Australia at 360BioLabs in March after being gifted SARS-CoV-2 samples [SARS-CoV-2-Australia/ VIC01/2020] for testing from The Peter Doherty Institute for Infection and Immunology (the Doherty Institute), with studies being completed in early July.

The studies showed that tafenoquine demonstrated low micromolar potency against SARS-CoV-2 and was approximately four times more potent than HCQ.

An arguably more important finding was that tafenoquine has a different mechanism of action to HCQ (and also remdesivir), acting late in the viral replication cycle in the release phase.

Australian Connection

Sixty Degrees is linked to Australia through a directorship held by Jennifer Herz from (Biointelect and Biocelect). Biocelect holds the Australian distribution rights for tafenoquine. Sixty Degrees has completed one clinical trial in Australia and has a long-term safety study underway in Perth.

Funding Objective

Sixty Degrees is seeking funding and research partners to further the clinical development of tafenoquine for use in mild-to-moderate COVID-19 cases and as a prophylactic in the post-exposure setting.

High Level of Interest in Potential SARS-CoV-2 Inhibitors

There is a high level of interest in potential SARS-CoV-2 inhibitors, with Recce's (RCE: \$1.36) share price having increased 423% since March 31, 2020, with recent gains being driven by a compound RECCE 327 being accepted into a screening program at the CSIRO and the Doherty Institute. Recce is capitalised at \$196 million.

Summary

An orally available, less toxic, potent and selective SARS-CoV-2 inhibitor, that has already been approved by leading drug regulators for malaria prophylaxis, is an attractive investment opportunity because its different mechanism-of-action to other aminoquinoline inhibitors may strengthen global capabilities needed to address potential resistance of SARS-CoV-2 to HCQ as well as remdesivir.

Stock Briefs

Clinuvel Pharmaceuticals Develops Liquid Formulation of Afamelanotide

Clinuvel Pharmaceuticals (CUV: \$23.40) has developed a new formulation of its drug Scenesse (afamelanotide). Scenesse is delivered in a solid form as a depot injection lasting two months. The new liquid formulation will presumably be injected.

Afamelanotide has a half-life in circulation of around 40 minutes. The new forumlation, called Prenumbra, will be used to tackle other diseases/disorders, including vascular abnormalities and conditions involving excess fluid build-up in life threatening disorders, as part of its strategy that had been in the planning for 10 years according to the company's Director of Global Operations, Lachlan Hay.

The aim with the new formulation is to provide greater flexibility in treating different conditions with a drug that now has a very safe track record from use in over 10 years in 1,400 patients. It also provides life cycle management for Scenesse.

Bioshares recommendation: Hold

NeuroScientific Biopharmaceuticals Adds Positive Preclinical MS Data

NeuroScientific Biopharmaceuticals (NSB: \$0.22) has released additional positive preclinical data for its neuro-regenerative drug candidate, EmtinB. The company had previously shown positive results in glaucoma in pigs and in a multiple sclerosis (MS) *in vitro* model.

An extension of that MS study has now shown that not just the level of the precursor cells to myelin sheath formation, oligodendrocytes, can be stimulated with EmtinB, but that the area of myelin sheath that protect the nerve fibres can be increased significantly in a dose dependent manner over the control. CEO Matt Liddelow stated that there are currently no therapeutics available for MS that can regenerate the myelin sheath surrounding nerves.

Bioshares recommendation: Speculative Buy Class B

Micro-X Receives Early Approval for Rover Mobile Xray Instrument

Micro-X (MX1: \$0.165) filed its second x-ray instrument, the Rover for military use, for approval last month and received clearance to sell the instrument in the US in just five weeks.

This opens up the opportunity for early orders from the US Army, Navy and Air Force. These will be direct sales so margins will be substantially higher for Micro-X. The Rover is a more rugged version of its hospital x-ray system, the Carestream DRX Revolution Nano, which is sold by Carestream. Whilst there is central purchasing in the US military, demonstrations will need to be made to multiple groups.

Direct sales of the Rover allows Micro-X to better control the sales and marketing through a narrower distribution channel to military organisations. Micro-X estimates the market for military

applications at over \$170 million. Micro-X CEO Peter Rowland is seeking to sign multiple year contracts with military groups.

Having gained US clearance, the company can deploy demonstration units in the US with these units now under construction in Adelaide. However, there will be challenges in demonstrating units during the current coronavirus pandemic.

Micro-X has had a very strong year so far with high orders for its Nano instrument from healthcare groups around the world for assisting in the diagnosis and progression of disease in COVID-19. To the end of May the company had built and shipped \$2.2 million worth of Nano instruments. Micro-X's current manufacturing capacity is between five to six units a week, which is expected to increase to eight units a week by August. We estimate the company has built around 200 units to date.

Market penetration and acceptance of the instrument from the emergency use to diagnose and manage COVID-19 should assist the company with sales of the Rover to military groups around the world.

The company is also seeking approval for the Rover in Australia and Europe, with interest from the UK military (and a potential procurement order later this year), and from the Department of Defence in Australia (through a tender sales process underway which is expected to be executed this year).

A high powered generator for the following version, Rover Mark II, is in development and is expected to be completed in 2021.

Bioshares recommendation: Speculative Buy Class A

two categories. The first group are stocks with existing positive cash flows or close to producing positive cash flows. The second group are stocks without near term positive cash flows, history of losses, or at early stages of commercialisation. In this second group, which are essentially speculative propositions, Bioshares grades them according to relative risk within that group, to better reflect the very large spread of risk within those stocks. For both groups, the rating "Take Some Profits" means that investors may re-weight their holding by selling between 25%-75% of a stock. Groun A	ioshares Nur	mber 852 – 20 July 2020	Page 7				
<pre>early singer of conducing positive cash flows. The second group of tasks without near term positive cash flows, history of losses, so relative risk within the group, to their second group with second group of relative risk within the group, to there reflect the very large producting positive cash flows, history of losses, so relative risk within the group, to there reflect the very large producting positive cash flows, there were used there were 25%-75% of a stock. Second group of the stocks with custum pre-weight their holding by ling between 25%-75% of a stock. Second group of the stocks with custum positive cash flows or close to producing positive cash flow custum positive cash flows or close to producing positive cash flow custum positive cash flows or close to producing positive cash flow custum positive cash flows or close to producing positive cash flow custum positive cash flows or close to producing positive cash flow custum positive cash flows or close to producing positive cash flow custum positive cash flows or close to producing positive cash flow custum positive cash flows or close to producing positive cash flow custum positive cash flows or close to producing positive cash flow custum positive cash flows or close to producing positive cash flow custum positive cash flows or close to producing positive cash flow custum positive cash flows or close to produce in a development and low may even be close to market. However, they are likely to be lacks CMP-Current Market Price) CMP is DSOS Flow Y Mule for the positive cash flows more than one produce in development and low may even build building features. Specialtive Bay <i>Journal Supposition</i>, https://sina. Specialtive Bay <i>Journal Supposition</i>, the positive cash flows more than one flows and the stocks position is the second position. Specialtic Bay <i>Journal Supposition</i>, flows inclose and the stock position is the stock position is the second position of the positive cash flows more than one flows and the second position of the positio</pre>	How Bioshares Rates Stoc	 :ks					
Second producing positive cash flows. The second group which are discussed of the second produce of any stages of commercialisation. In this second group, which are discussed percent of the second produce of produce of any stages of commercialisation. In this second group, which are discussed percent of the second produce of any stages of commercialisation. In this second group, which are discussed percent of the second produce of th	or the purpose of valuation, Bios	shares divides biotech stocks into	Stocks without near term positive cash flows, history of losses, or at				
science Speculative Buy - Class A These sciences will have more than one technology, product or investment in development, with perhaps indicate the science science of alliances, partnerships and sciencific advisory boards indicate the science is relative is set with perhaps the indice science of alliances, partnerships and sciencific advisory boards indicate the science is relative is set with perhaps their advisory boards indicate the science is relative is set singly than other biotic stocks. Sympa CMP is 20% of a stock. Top A CMP is 10% < Frair Value			early stages commercialisation.				
<pre>initially speculative propositions. Bioshares grades them according relative rade with in that group, to better reflect the very large relative rade with in those stocks. These features, coupled to the presence of alliances, partnerships and scientific advisory boards indicate the stocks is relative less risks than other biotech stocks. Speculative Buy C MP is 10% > Fair Value commuter C MP is 10% > Fair V</pre>							
relative risk within that group, to better reflect the very large- relation of sk within that group, to better reflect the very large- relation of sk within those stocks. For both groups, the rating "Take merodical measures had investors any re-weight their holding by ling between 25%-75% of a stock. ToropA offer firing multiple opportunities. These features, coupled to the presence of alliances, partnerships and actinities divery band within those stocks. Speculative Harmon Ends on product or opportunity, and may even be tools to market. However, they are likely to be lack several by areas. For example, their cash position is weak, or management or board may need strengthening. Speculative Hold - Class A or B or C Settingen Medical, Patrys, Cyclopharm, Envision, Antisense Therapeutics, Heramed, Imagene, Exopharm, Immutep, euroscientific Biopharmaceuticals, Invex Therapeutics entime onto patient and associate of the public and are stoget to any even breactions and the metaster of more and equations of the public and are stoget to alway. Black Industry and Market always by Dui (BMA) and any of the associate, of many seven the constration contained and are stoget to always. Black Industry and Market always by Dui (BMA) and any of the associate, of any have inter- sentes. Endower and pressing stock is a provide to a stoget or the public and are stoget on the public and are stoget on the public and are stoget or the provide the in the stocetary charge and pressing stock is a provide to a stoget or the public and are stoget or the public and are stoget or the provide the in the stocetary charge and pressing stock is a provide to a partner for the public and are stoget or the public and are stoge	rly stages of commercialisation.	In this second group, which are					
<pre>reread of risk within those stocks. For both groups, the rain, "Take me Profils" means that investors may re-weight their holding by me Profils" means that investors may re-weight their holding by me Profils" means that investors may re-weight their holding by me Profils" means that mestors are re-weight their holding by me Profils" means that mestors are re-weight their holding by me Profils" means that mestors are re-weight their holding by me Profils" means that mestors are re-weight their holding by me Profils" means that mestors are provided to a profile their holding by me Profils" means that mestors are than one product or opportunity, an may even be close to market. However, their cash position is seak, or management or board may need strengtheming. Speculative Buf - Class A or B or C Self Torporate Subscribers: Cogstate, Bionomics, LBT Innovations, Opthea, ResApp Health, Pharmaxis, Dimerix, Adalta, ctinogen Medical, Patrys, Cyclopharm, Enwision, Antisense Therapeutics, Heramed, Inugene, Exopharm, Innutep, cervoscientific Biopharmaccuticals, Invex Therapeutics Profile CMP is 10% + Fair Value Profile CMP is 10% + Gair Valu</pre>							
one Profile" means that investors may re-weight their holding by implement 25%-75% of a stock. Specialize Bug - Class B indicate the stock is relative less relative less nearby that is the stock is relative less relative less relative less nearby that other product or opportunity, a may even be close to market. However, they are likely to be lack of a stock. with existing positive cash flows or close to produce or opportunity. These stocks may have more than one product or opportunity, a may even be close to market. However, they are likely to be lack of which the close to market. However, they are likely to be lack of which we can produce to opportunity. These stocks panently have noe product in development and lack may external validation features. With CMP is 10% > Fair Value These stocks panently have one product in development and lack may external validation features. Korporate Subscribers: Cogstate, Bionomics, LBT Innovations, Opthea, ResApp Health, Pharmaxis, Dimerix, Adalta, clinogen Medical, Patrys, Cyclopharm, Envision, Antisense Therapeutics, Heramed, Imagene, Exopharm, Immutep, lettroscientific Biopharmaceuticals, Invex Therapeutics Restaure Settimer:			presence of alliances, partnerships and scientific advisory boards,				
<pre>https://www.intercontents/intercontents</pre>	ome Profits" means that investor	rs may re-weight their holding by					
nocks with existing positive cash flows or close to producing positive cash invs. invs. invs. invs	-	ick.	These stocks may have more than one product or opportunity, and				
ows. Several key areas. For example, invariant each possibility is weak, or management or board may need strengthening. syncurity the CMP is 10% < Fair Value cample.	-	ws or close to producing positive cash	may even be close to market. However, they are likely to be lacking in				
up CMT B 200% F all Value commutate CMT B 200% F all Value old Value = CMP ight on CMP B 10% F all Value CMT B 200% F all Value CMP ight on CMP B 10% F all Value CMT D 200% F all Value CMP CMT D 200% F all Value Specialitive Buy - Class C Components Subscribers: Cogstate, Bionomics, LBT Innovations, Opthea, ResApp Health, Pharmaxis, Dimerix, Adalta, etinogen Medical, Patrys, Cyclopharm, Envision, Antisense Therapeutics, Heramed, Imugene, Exopharm, Immutep, teuroscientific Biopharmaceuticals, Invex Therapeutics sclaimer: Emergencine Subscribers: Cogstate, Bionomics, LBT Innovations, Opthea, ResApp Health, Pharmaxis, Dimerix, Adalta, etinogen Medical, Patrys, Cyclopharm, Envision, Antisense Therapeutics sclaimer: Emergencine Subscribers, Strongia Subscription Reset and Subscription and previous sclauge to the positions and stinutes herein expressed regreered industry or security. The opinions and stinutes herein expressed regreered industry on strengen Subscription Reset and Subscription Reset and Subscription Reset and Subscription Reset (Res. CRST) sclaimer Subscription Reset (Inc. CST) All scale and envines is green and previse scription form to: Bioshares PO Guo Y 133 Richmond VIC 3121 Fax: +61 3 3329 3350 I enclose a cheque for \$ made payable to Blake Industry & Market Analys							
oid Value = CMP ighten CMP is 10% > Fair Value et1 CMP is 20% > Fair Value MP-Current Market Price) Speculative Hold-Class A or B or C Scripporate Subscribers: Cogstate, Bionomics, LBT Innovations, Opthea, ResApp Health, Pharmaxis, Dimerix, Adalta, ctinogen Medical, Patrys, Cyclopharm, Envision, Antisense Therapeutics, Heramed, Imugene, Exopharm, Immutep, euroscientific Biopharmaceuticals, Invex Therapeutics isolator: Speculative Hold-Class A or B or C isolator: Speculative Hold - Class A or B or C isolator: Speculative Hold - Class A or B or C isolator: Speculative Hold - Class A or B or C isolator: Speculative Hold - Class A or B or C isolator: Speculative Hold - Class A or B or C isolator: Speculative Hold - Class A or B or C isolator: Speculative Hold - Class A or B or C isolator: Speculative Hold - Class A or B or C isolator: Speculative Hold - Class A or B or C isolator: Speculative Hold - Class A or B or C isolator: Speculative Hold - Class A or B or C isolator: Speculative Hold - Class A or B or C isolator: Speculative Hold - Class A or B or C isolator:			Speculative Buy – Class C				
Build of the problem	old Value = CMP						
Signal Self Signal Self Corporate Subscribers: Cogstate, Bionomics, LBT Innovations, Opthea, ResApp Health, Pharmaxis, Dimerix, Adalata, clinogen Medical, Patrys, Cyclopharm, Emvision, Antisense Therapeutics, Heramed, Imugene, Exopharm, Immutep, euroscientific Biopharmaceuticals, Invex Therapeutics Industry of the phase on the phase of the phas	8		•				
Corporate Subscribers: Cogstate, Bionomics, LBT Innovations, Opthea, ResApp Health, Pharmaxis, Dimerix, Adata, clinicogen Medical, Patrys, Cyclopharm, Emvision, Antisense Therapeutics, Heramed, Imugene, Exopharm, Immuter, euroscientific Biopharmaceuticals, Invex Therapeutics isolance: Enventoid in this newaletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates herein expressed represented for general discussion of the publishead made subject to change. Blake Industry and Market Analysis PV Ld (MAN) and any of their associates, officers or strained in this document wave manufus that investment adviser (Corporations Law s.81). The persons involved in or responsible for the preparation and publication of this repress below the sin massociates within the inducember of the publishead metabers. Publication and so any economediation (whether express or inplice) contained in this document wave manufus that investment adviser (Corporations Law s.81). The persons involved in or responsible for the preparation and publication of this preprise below the himmation accurates but on division genes and hotechnologies selection set view and the preparation and publication of this preprise below the himmation accurates but on division genes and hotechnologies selection set view and are not additional recommendations. Holdings in stock valued at less that \$100 are not date set of the the influences in the following and Market Manlysis PUL (MANCONTSOULTX.Analyst PUL ACRO, PUL (MANCONTSOULTX.ANALOPSTANCLX.ANA		ir value	-				
teriorgen Medical, Patrys, Cyclopharm, Emvision, Antisense Therapeutics, Heramed, Imugene, Exopharm, Immutep, instance intervention of the polyhermaceuticals, Invex Therapeutics instance intervention of the polyhermaceuticals, Invex Therapeutics instance in the newsletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates herein expressed pre- e carrent judgement of the publisher and are subject to change. Black Industry and Market Analysis PV Lid (BIMA) and yof their associates, officers or staff mary have infor- central judgement of the publisher and are subject to change. Black Industry and Market Analysis PV Lid (BIMA) and yof their associates, officers or staff mary have infor- accurate but no warranty of accuracy is given and persons scelarities involved in or responsible for the periation of this report bleve the information accurate but no warranty of accuracy is given and persons scelarities: Analysis DB: ACR,ADR,COLS,CYCAXI,OPT,SOM,TLX Analysis PV Lid. The Director is sociated declare interests in the following ASX Healthear and Biotechnology sector securities: Analysis DB: ACR,ADR,COLS,CYCAXI,OPT,SOM,TLX Analysis PV Lid. The Director is sociated declare interests in the following ASX Healthear and Biotechnology sector securities: Analysis DB: ACR,ADR,COLS,CYCAXI,OPT,SOM,TLX Analysis PV Lid. The Director is sociated declare interests in the following ASX Healthear and Biotechnology sector securities: Analysis DB: ACR,ADR,COLS,CYCAXI,OPT,SOM,TLX Analysis PV Lid. The Therefore is used on the basis they are only person or company is within S800 2.3 email addresses [br circing structure is as follows: S1370 6-10 email addresses [br circing structure is as follows: S1370 6-10 email addresses [br circing structure is as follows: S1370 6-10 email addresses [br circing structure is as follows: S1370 6-10 email addresses [card Number	,						
terring Medical, Patrys, Cyclopharm, Emvision, Antisense Therapeutics, Heramed, Imugene, Exopharm, Immutep, learners: Instance in the probability of the pricinal set of the presence of the pricinal of the respecting any company, industry or security. The opinions and estimates herein expressed per e current judgement of the publisher and are subject to change. Black Industry and Market Analysis Py Lid (BIMA) and yor of their associates, officers or staff mary have information accurate but no warrany of accuracy is given and persons seeking to rely on information provided herein should market therein weighted contained in this how seeking revolution and publisher and are subject to change. Black Industry and Market Analysis Py Lid (BIMA) and and Market Analysis Py Lid (Bine Corponitons Law s. 48). The persons involved in or responsible for the pricinal on of this report bleve the information accurate but no warrany of accuracy is given and persons scelarities: Analysis DB: ACR.ADR.COLS.CVC.MXI.OPTSOM.TLX Analysis Py Lid. The Director is associates declare interests: in the following ASX Healthear and Biotechnology sector securities: Analysis DB: ACR.ADR.COLS.CVC.MXI.OPTSOM.TLX Analysis Py Lid. The Director is associates declare interests: in the following ASX Healthear and Biotechnology sector securities: Analysis DB: ACR.ADR.COLS.CVC.MXI.OPTSOM.TLX Analysis Py Lid. The Director is associates declare interests: in the following ASX Healthear and Biotechnology sector securities: Analysis DB: ACR.ADR.COLS.CVC.MXI.OPTSOM.TLX Analysis Py Lid. The Director is associates declare interests: in the following ASX Healthear and Biotechnology sector securities: Analysis DB: ACR.ADR.COLS.CVC.MXI.OPTSOM.TLX Analysis Py Lid. The Director is associates declare interests: in the following ASX Healthear and Biotechnology sector securities: Analysis DB: ACR.ADR.COLS.CVC.MXI.OPTSOM.TLX Analysis Py Lid. The Sinter Sint	orporate Subscribers:	Cogstate, Bionomics. LBT Innov	ations, Opthea, ResApp Health, Pharmaxis, Dimerix, Adalta.				
In example, and the example of the particular complete analysis of every material fast respecting any company, industry or security. The opinions and estimates been increases and existing the increase of the publisher and are subject to change. Blake Industry and March Analysis Pty Lid (BIMA) and any of their associates, officers or staff may have inter- centrent judgement of the publisher and are subject to change. Blake Industry and March Analysis Pty Lid (BIMA) and any of their associates, officers or staff may have inter- perivers, financial situation and particular needs. Accordingly, no recipients involved in or responsible for the periodical or of their expension of the staff and person is company to when they three been provided by Black Industry and March Analysis Pty Lid. The Directors is accurate but no warranty of accuracy is given and person scelaring to who may they have been provided by Black Industry and March Analysis Pty Lid. The Directors is accurate but no warranty of accuracy is given and person are company in whom they have been provided by Black Industry and March Analysis Pty Lid. The Directors is accurate but no warranty of accuracy is given and person are company in whom they have been provided by Black Industry and March Analysis Pty Lid. The Directors is accurate but no warranty of accuracy is given and person are company in whom they have been provided by Black Industry and March Analysis Pty Lid. The Directors is accurate but no warranty of accuracy is given and person are company is invested at less than \$100 are not date to insue on the following ASS Healthear and Bloitechnology sector securities: Analysi DB. ACR, ADR, COL, COL, XLX, ANALO, SOM. These interests and charces are function is staff and the staff and the sectors in the following ASS Healthear and Bloitechnology sector securities: Analysis Pty Lid. The Directors is sociated acclure interests in the following ASS Healthear and Bloitechnology sectors is a staff and the sectors is a staff and the sector is a staf	-	•					
<pre>domain contained in this newsletter is not a complete analysis of every material flat respecting any company, industry the optical associates, officers or stiff may have intere every settered to berein (Corporations Law \$849). Details contained berein have been prepared for general circulation and do not have regard to any person is or company is inverse to the possibility of the preparadicity (MeMA) and any of their associates, Contained Pereir have been prepared for general circulation and publication of this report believe the information accurate but the varianty of accurates of the possibility of the preparadicity (MeMA) and any of their associates, Contained Pereir have been provided by Pereir solutid and their on their exponses or implete on their responses believe the information accurate but the varianty of accurates of the possibility of the preparadicity and Market Analysis PUL ATE Directors: Corporations Law \$851). The persons involved in our esponsibility of the preparadicity and Market Analysis PUL ATE Directors: Corporations Law \$850). These interests are change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 are not accord to every (Corporations Law \$850). These prevent (electronic distributions): Stoce (Corporations Law \$850). These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 are not accord to every (Corporations Law \$850). These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 are not accord to every (Corporations Law \$850). The person is moved by the precedence of \$100 and \$100 are not accord \$100 are not ac</pre>	leuroscientific Biopharmaceut	ticals, Invex Therapeutics					
<pre>binding on unitained in this newsletter is not a complete analysis of every material flat respecting any company, industry of the private material statistica and are subject to hange. Black Industry and Market Analysis PV (14 (BMA) and any of their associates, contained herein have been prepared for general identifiable and do not have regard to any person's or company's inversive fragment is and a subject of the private inter associates, contained herein have been prepared for general identifiable and do not have regard to any person's or contained in this document with subject of the preparation and publication and publications and without have been provided by Black chalasty and Market Analysis PV Lut. The Directors: Corporations 14 with subject of the information in private herein have the private material flat respective. The person involved here in house their own and contained therein have the person and publication and publication and publication and publications. Black CAR, DAR, CAR, CAR, CAR, CAR, CAR, CAR, CAR, C</pre>	sclaimer:						
<pre>uprives referred to berefin (Corporations Law s.849, Details contained herein have been prepared for general circulation and do not have regard to any person's or company's investigatives, frank-distantiation and publication of this report believe the information accurate but no variantly diaceuraly signed and persons services and sub of the Approxamion and publication of this report believe the information accurate but no variantly diaceuraly signed and persons services can sub DB ACR.ADR.COMC.CUY.CUY.MX1.PXS.RNO.SOM. These interests in the following ASX Hendharze and Biotechnology sector scentines: Analys DB ACR.ADR.COMC.CUY.CUY.DTSDMTLX Analys DP ACR.COMC (C.YC.C.W.I.OPTSDMTLX Analys DP). ACR.COMC (C.Y.C.Y.C.W.I.OPTSDMTLX Analys DP). ACR.COMC (C.Y.C.Y.C.W.I.OPTSDMTLX Analys DP). ACR.COMC (C.Y.C.Y.C.W.MX1.PXS.RNO.SOM. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 are not additional recommendations. Holdings in stocks valued at less than \$100 are not additional recommendations. Holdings in stocks valued at less than \$100 are not additional recommendations. Holdings in stocks valued at less than \$100 are not additional recommendation. Stopped at less than \$100 are not additional recommendation. Stopped at less than \$100 are not additional recommendation. For the stopped at less than \$100 are not additional recommendation. For the stopped at less than \$100 are not additional recommendation. For the stopped at less than \$100 are not additional recommendation. For the stopped at less than \$100 are not additional recommendation. Holdings in stocks valued at less than \$100 are not additional recommendation. For the stopped at less than \$100 are not additional recommendation. For the stopped at less than \$100 are not additional recommendation. For the stopped at less than \$100 are not additional recommendation. For the stopped at less than \$100 are not additional recommendation. For the stopped at less than \$100 are not additional recom</pre>	formation contained in this newsletter is no						
insulting their investment adviser (Corporations Law 3.831). The persons involved in or responsible for the pranation and publication of this report believe the information securities the varanty of accurately is given and persons sections contrained persons sections contrained persons of the particular person or company to whom they have been provided by Blake Industry and Market Analysis Py Lid. The Directors sociates declare interests in the following ASX Healthcare and Biotechnology sector securities: Analyst DB: ACR.ADR.COH.CSL.CYC.MX1.OPT.SOM.TLX Analyst DP: ACR Yee, OPT.CUV_MX1.PXS.RNO,SOM. These interests can change at any time and are not addifional recommendations. Holdings in stocks valued at less than \$100 are not data Subscription Rates (inc. GST) AS issues per year (electronic distributions): \$500 For multiple email distributions within \$800 2-3 email addresses pricing structure is as follows: \$1370 6-10 email addresses fue colose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$ MasterCard Visa Signature							
accurate but no warrany of accuracy is given and persons seeking to rely on information provided here in solud make their own independent enquires. Details contained berein source and basis they are only for the particular person or company to whom they have been provided by Black fluctures. Analyst DB: ACR, ADR, COH, CSL, CYC, MX1, OPT, SOM, TLX Analyst MP: ACR YC, OPT, CUV, MX1, PXS, RNO, SOM. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 are not details Subscription Rates (inc. GST) . As issues per year (electronic distributions): \$500 . Tor multiple email distributions within \$800 2-3 email addresses the same business cost centre, our \$1100 4-5 email addresses pricing structure is as follows: \$1370 6-10 email addresses PO Box 193 Richmond VIC 3121 Eax: +61 3 93229 3350 I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$ MasterCard Visa Signature							
secience decline interests in the following ASX Healthcaire and Biotechnology sector securities: Analysi DB: ACR.ADR.COH.CSL, CYC.MX1.0PT.SOM.TLX Analyst MP: ACR YC, OPT.CUV,MX1,PXS,RNO,SOM. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 are not disc Subscription Rates (inc. GST) 48 issues per year (electronic distributions): \$500 For multiple email distributions within \$800 2-3 email addresses the same business cost centre, our \$1100 4-5 email addresses pricing structure is as follows: \$1370 6-10 email addresses PO Box 193 Richmond VIC 3121 Fax: +61 3 9329 3350 I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$ MasterCard Visa Signature Expiry date Signature Expiry date Name Organisation Ph ()	accurate but no warranty of accuracy is g	given and persons seeking to rely on information	provided herein should make their own independent enquiries. Details contained herein have				
Subscription Rates (inc. GST) 48 issues per year (electronic distribution): \$500 For multiple email distributions within \$800 2-3 email addresses the same business cost centre, our \$1100 4-5 email addresses pricing structure is as follows: \$1370 6-10 email addresses To subscribe, post/fax this subscription form to: Bioshares PO Box 193 Richmond VIC 3121 Fax: +61 3 9329 3350 I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$ MasterCard Visa Card Number	ssociates declare interests in the following	ASX Healthcare and Biotechnology sector securit	ties: Analyst DB: ACR, ADR, COH, CSL, CYC, MX1, OPT, SOM, TLX Analyst MP: ACR, CGS,				
48 issues per year (electronic distribution): \$500 For multiple email distributions within \$800 2-3 email addresses pricing structure is as follows: \$1100 4-5 email addresses pricing structure is as follows: \$1370 6-10 email addresses To subscribe, post/fax this subscription form to: Bioshares PO Box 193 Richmond VIC 3121 Fax: +613 9329 3350 I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$ MasterCard Visa Card Number	YC, OPT,CUV,MX1,PXS,RNO,SOM. T	hese interests can change at any time and are not	t additional recommendations. Holdings in stocks valued at less than \$100 are not disclosed.				
48 issues per year (electronic distribution): \$500 For multiple email distributions within \$800 2-3 email addresses pricing structure is as follows: \$1100 4-5 email addresses pricing structure is as follows: \$1370 6-10 email addresses PO Box 193 Richmond VIC 3121 Fax: +61 3 9329 3350 I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$ MasterCard Visa Card Number		Subscription R	ates (inc. GST)				
the same business cost centre, our pricing structure is as follows: \$1100 4-5 email addresses To subscribe, post/fax this subscription form to: Bioshares PO Box 193 Richmond VIC 3121 Fax: +61 3 9329 3350 I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$ MasterCard Visa Card Number							
pricing structure is as follows: \$1370 6-10 email addresses To subscribe, post/fax this subscription form to: Bioshares PO Box 193 Richmond VIC 3121 Fax: +61 3 9329 3350 I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$ MasterCard Visa Card Number Expiry date Signature Expiry date Ph ()							
To subscribe, post/fax this subscription form to: Bioshares PO Box 193 Richmond VIC 3121 Fax: +61 3 9329 3350 I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$ MasterCard Card Number Image: Card Number Signature Expiry date Subscriber details Name Image: Card Number Organisation Image: Card Number Ph (Image: Details of the second se							
PO Box 193 Richmond VIC 3121 Fax: +61 3 9329 3350 I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$ MasterCard Visa Card Number Signature Subscriber details Name Organisation Ph ()		priority structure is as follows.	\$1570 0-10 chian audresses				
Fax: +61 3 9329 3350 I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$ MasterCard Visa Card Number	To subscribe, post/fax	this subscription form to:	Bioshares				
I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$ MasterCard Card Number Image: Card Number Signature Expiry date Subscriber details Name Organisation Ph ()			PO Box 193 Richmond VIC 3121				
Please charge my credit card \$ MasterCard Card Number Signature Subscriber details Name Organisation Ph ()			Fax: +61 3 9329 3350				
Card Number Card N	I enclose a cheque for	r \$ made payable to I	Blake Industry & Market Analysis Pty Ltd, or				
Signature Subscriber details Name Organisation Ph ()	Please charge my cree	dit card \$ Master	Card Visa				
Subscriber details Name Organisation Ph ()	Card Number						
Subscriber details Name Organisation Ph ()	Signatura		Evnimedata				
Name	e						
Organisation Ph ()							
Ph ()	Name						
	Organisation						
Emails	Ph ()						
	Emails						
he information provided in Bioshares, including general investment advice, is provided only for receipt and use in Australia	ne information provided in Di	oshares including general investo	nent advice, is provided only for receipt and use in Australia and				